Kathleen A. Maguire-Zeiss

Somatic mosaic approaches and the aging brain.

Convergent pathobiologic model of Parkinson's disease.

Safety of viral vectors for neurological gene therapies.

Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?

Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector.

Identification of human alpha-synuclein specific single chain antibodies.

Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

Synuclein activates microglia in a model of Parkinson's disease.

Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.

alpha-Synuclein: a therapeutic target for Parkinson's disease?

Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Mutant alpha-synuclein overexpression mediates early proinflammatory activity.

Gene therapy in Parkinson's disease: rationale and current status.

Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

α-Synuclein Alters Toll-Like Receptor Expression.

Misfolded α-synuclein and Toll-like receptors: therapeutic targets for Parkinson's disease.

Matrix metalloproteinase dependent cleavage of cell adhesion molecules in the pathogenesis of CNS dysfunction with HIV and methamphetamine.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Parkinson's disease.

Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease.